BC Week In Review | Oct 28, 2013
Clinical News

Compugen preclinical data

In a mouse model of psoriasis, CGEN-15001 was "highly efficient" in preventing disease development in engrafted skin. Data were presented at the Autoimmune and Inflammation Leaders' Forum in Boston. Compugen declined to disclose details or...
BC Week In Review | Oct 28, 2013
Clinical News

Compugen preclinical data

In non-obese mice that spontaneously develop autoimmune insulin-dependent diabetes, CGEN-15001 given for 2 weeks prior to manifestation of clinical symptoms prevented the development of Type I diabetes through 4 months of follow-up. Additionally, mice treated...
BC Week In Review | Oct 28, 2013
Clinical News

Compugen preclinical data

In a mouse model of bone marrow transplantation, successful engraftment was achieved in animals treated with CGEN-15001 whereas transplanted cells were rejected in control animals. Data were presented at the Autoimmune and Inflammation Leaders' Forum...
BC Week In Review | Sep 26, 2011
Clinical News

Compugen preclinical data

Compugen announced in vitro validation of CGEN-15091, its third drug candidate based on the B7/ CD28 co-stimulatory protein family with therapeutic potential in autoimmune diseases and cancer. CGEN-15091, along with Compugen's CGEN-15021 and CGEN-15001 , are...
BioCentury | Jul 25, 2011
Product Development

Predicting a pipeline

Compugen Ltd. has spent more than a decade developing and refining its in silico prediction platform to discover novel peptides and proteins that can be developed as therapeutics or targets. The company has neither the...
BC Week In Review | Jun 27, 2011
Clinical News

Compugen preclinical data

Compugen announced in vitro validation of CGEN-15021, its second candidate based on the B7/ CD28 co-stimulatory protein family with therapeutic potential in autoimmune diseases and cancer. CGEN-15021 and Compugen's first candidate, CGEN-15001 , are fusion proteins...
BC Week In Review | Jun 27, 2011
Clinical News

Compugen preclinical data

Compugen announced in vitro validation of CGEN-15021, its second candidate based on the B7/ CD28 co-stimulatory protein family with therapeutic potential in autoimmune diseases and cancer. CGEN-15021 and Compugen's first candidate, CGEN-15001 , are fusion proteins...
BC Extra | Jun 22, 2011
Clinical News

Compugen validates second B7/CD28 candidate

Compugen Ltd. (NASDAQ:CGEN) announced in vitro validation of CGEN-15021, its second candidate based on the B7/ CD28 co-stimulatory protein family with therapeutic potential in autoimmune diseases and cancer. CGEN-15021 and Compugen's first candidate, CGEN-15001 , are...
BC Week In Review | Jan 3, 2011
Clinical News

Compugen preclinical data

In a mouse model of RA, CGEN-15001 ameliorated disease symptoms and displayed similar efficacy to that of Enbrel etanercept. CGEN-15001 is a recombinant fusion protein corresponding to the extracellular region of a membrane protein in...
BC Week In Review | Jul 19, 2010
Clinical News

Compugen preclinical data

In a mouse model of RRMS, CGEN-15001 resulted in complete eradication of spontaneous relapses when administered after disease onset. When administered before disease onset, CGEN-15001 demonstrated a pronounced delay of disease onset and a significant...
Items per page:
1 - 10 of 11